Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 184 results

Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Basic Experimental Studies with Humans Required)

PA
Monday, May 11, 2020
Monday, May 8, 2023
K23
PA-20-204

Funding Opportunity Purpose

The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.

Notice of Special Interest: Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) - U.S. Entity (Admin Supp)

Notice of Special Interest
Thursday, May 7, 2020
Thursday, September 8, 2022
333
NOT-NS-20-024

Funding Opportunity Purpose

Notice Special Interest: Administrative Supplements the U.S.-Japan Brain Research Cooperative Program BRCP) - U.S. Entity Admin Supp) Notice Number: NOT-NS-20-024 Key Dates Release Date: 05, 2020 First Available Due Date: September 07, 2020 Expiration Date:September 08, 2022 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) National Institute Aging NIA) National Institute Biomedical Imaging Bioengineering NIBIB) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Mental Health NIMH) National Center Complementary Integrative Health NCCIH) Purpose National Institutes Health NIH) announces continuation the U.S. entity the U.S.-Japan Brain Research Cooperative Program BRCP). administrative supplement program provide funds currently active research grants are currently supported one the participating NIH Institutes Centers. Notice soliciting administrative supplements the following mechanisms ONLY: DP1, DP2, DP5, R01, R03, R21, R33, R34, R37, R61, U01, UH2, and UH3. purpose the BRCP to promote scientist exchange, training, collaborations basic, translational clinical research between neuroscientists the U.S. Japan. U.S. entity the BRCP supports following activities: 1) Visit U.S. scientists conduct collaborative research and/or acquire advanced research skills Japanese institutions, 2) Joint workshops exchange scientific information to foster collaborations. Background agreement ldquo;Cooperation Research Development Science Technology” signed the President the United States the Prime Minister Japan May 1, 1980, has subsequently renewed extended. Under umbrella this Agreement, National Institute Neurological Disorders Stroke NINDS) the National Institute Physiological Sciences NIPS), Okazaki National Research Institutes, Japan, signed Memorandum Understanding a Brain Research Cooperative Program BRCP) November 29, 2000. Since inception the U.S. BRCP 2002, NIH successfully supported U.S. neuroscientists’ collaborative activities Japanese institutions, joint workshops the neurosciences. Japanese entity the BRCP been active since 2001. Details the program available http://www.nips.ac.jp/jusnou/english/. Within funding guidelines the BRCP program, country supports own scientists participate the aforementioned activities. BRCP Activities Supported the NIH A. Collaborative Research Fund Collaborative Research Fund provides support the travel lodging expenses the U.S. scientist’s visit Japan. visit the institution Japan be performed the PD/PI, collaborators, postdoctoral fellows students work the collaborative project. Support the Collaborative Research Fund be used one multiple trips. duration the supplement one year. supplement be carried over the next fiscal year, prior approval NIH Program staff. B. Workshop Fund U.S. Workshop Fund provides partial support joint workshops. U.S. Japan funding agencies the BRCP provide parallel support joint-workshops. entity support travel lodging expenses the joint-workshop participants their own country. the joint workshop be held the U.S., U.S. entity the BRCP support logistical meeting expenses. the joint workshop be held Japan, Japan entity support logistical meeting expenses. proposed workshop should at least co-organizer the U.S. one Japan. Co-organizers encouraged work together develop workshop applications. U.S. co-organizer must an active grant a participating NIH Institute Center. Workshop applications U.S. co-organizers should submitted response this FOA. Similarly, co-organizers Japan should submit application the NIPS. See: http://www.nips.ac.jp/jusnou/eng/ Applicants encouraged use Workshop Fund compensate travel lodging individuals groups are underrepresented the biomedical, clinical, behavioral social sciences encourage participation, the planning implementation of, well participation in, proposed workshop. NOT-OD--20-031. support junior investigators, postdoctoral fellows, graduate students also encouraged. Areas research interests the participating NIH Institutes Centers NINDS supports basic, translational clinical research understand structure function the nervous system mechanisms underlying neurological disorders stroke. Awardees projects funded the NIH BRAIN Initiative braininitiative.nih.gov/) encouraged submit supplement requests collaborative efforts are within scope this FOA NIH’s goals the BRAIN Initiative, defined the strategic planning report, BRAIN 2025: Scientific Vision. Investigators encouraged contact potential collaborators participating related efforts led Japan such the Brain/MINDS project http://brainminds.jp/en/). Collaborations promote interdisciplinary approaches research questions within NINDS mission also strongly encouraged. NIA supports broad spectrum research training aimed a better understanding age-related normal pathological changes the structure function the nervous system how such changes affect behavior. addition, NIA encourages cross-country collaborations research related the etiology, diagnosis, progression, treatment Alzheimer’s Disease AD). mission includes basic clinical studies the nervous system, clinical trials interventions therapeutic modalities, epidemiological research identify risk factors to establish prevalence incidence estimates pathologic conditions aging AD. mission NIBIB to improve human health leading development accelerating application biomedical technologies. NIBIB encourages submission applications support development bioengineering biomedical imaging technologies. NIDA supports basic, clinical, applied research the causes, consequences, prevention treatment drug abuse addiction. NIDCD encourages collaborative basic clinical biomedical bio-behavioral research the communication sciences hearing, balance, smell, taste, voice, speech language. NIDCR supports wide range basic, clinical translational research painful disorders the orofacial region including temporomandibular joint disorders, trigeminal neuropathies, burning mouth syndrome, oral cancer pain, dental pain, other conditions; well chronic pain conditions co-morbid orofacial pain. NIEHS supports basic mechanistic human based studies the interplay environmental neurotoxicant exposure neuronal dysfunction across life span. includes influence prenatal exposure both childhood adult dysfunction/disease well adult exposures the aging brain. NIMH supports research transform understanding treatment mental illnesses through basic, translational, clinical, services research, paving way prevention, recovery, cure. NIMH encourages innovative thinking ensure a full array novel scientific perspectives used further discovery the evolving science brain, behavior, experience. NIMH now focusing an experimental medicine approach evaluating novel interventions mental illnesses. strategy designed increase value the public investment early clinical trials ensuring informed, data-driven decisions an early stage behavioral, device, pharmacologic studies. NCCIH supports rigorous scientific investigation, usefulness safety complementary integrative health approaches, their roles improving health health care. includes collaborations involving studying neurobiological mechanisms natural products such herbs, prebiotics, probiotics, dietary supplements) mind body interventions such acupuncture, meditation, manual therapy, yoga, Tai Chi, hypnosis, music art therapy, etc) their effects pain, sleep, stress, anxiety, emotional well-being, and/or behavioral changes. NCATS supports development disruptive innovative methods technologies will enhance development, testing implementation diagnostics therapeutics across wide range human diseases conditions. includes translational early stage clinical research rare neurologic brain conditions. Award Project Period be eligible, parent award must active the current fiscal year i.e., parent award received funds the current fiscal year is in extension period), the research proposed the supplement should requested one year should accomplished within currently approved project period the existing parent award. awarding institute consider no-cost extension up an additional year the conclusion the first year. Award Budget Application budgets Collaborative Research Funds limited 25,000 direct cost. to 2,500 be used research supplies. Funds the BRCP not used salary support the PD/PI, collaborators, postdoctoral fellows, students collaborators. Travel costs associated Collaborative Research Fund requests should exceed U.S. Government Foreign Per Diem Rates Japan. See: http://aoprals.state.gov/content.asp?content_id=184&menu_id=81/ Application budgets Workshop Funds limited 35,000 direct cost. support travel lodging expenses should exceed U.S. Government Per Diem Rates http://www.gsa.gov/portal/content/101518 ; or http://aoprals.state.gov/content.asp?content_id=184&menu_id=81/ ). honorarium allowed. is recommended investigators secure additional funding support other sources, needed. announcement for supplements existing projects. research proposed the NIH grantee the supplement application must within original scope the NIH-supported grant award. Similarly, scope the proposed collaborative research activities workshops should well aligned the aims the parent award. Eligible Individuals Program Director/Principal Investigator) Individual(s) must hold active grant award one the participating NIH Institutes Centers. supplements parent awards include multiple PDs/PIs, supplement be requested any all the PDs/PIs accordance the existing leadership plan) must submitted the awardee institution the parent award. New early stage investigators encouraged apply, well established neuroscientists. Individuals diverse backgrounds, including underrepresented racial ethnic groups, individuals disabilities, women always encouraged apply NIH support. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed, the following additions: Application Due Date(s) – September 7, 2020, September 7, 2021, September 7, 2022, 5:00 PM local time applicant organization. funding consideration, applicants must include ldquo;NOT-IC-20-024” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. Research Strategy section the application limited 6 pages. Only existing awardees a participating Institute Center eligible apply. Administrative supplement applications to PA-18-591 must the application form package the Competition ID contains ldquo;FORMS-F-ADMINSUPP”. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify program contact the Institute supporting parent award a request been submitted response this FOA order facilitate efficient processing the request. Page Limits: NIH consider supplements a Research Strategy no than 6 pages, addition the abstract. Research Strategies Collaborative Research Fund Submitted applications collaboration/training must include: Description the goals the collaboration/training how will enhance research the NIH-supported parent grant Details the supplement's specific aims, research design, methods data analysis Background significance the proposed research/training its relevance the goals the BRCP the mission the participating NIH Institutes Centers unique opportunities offered this collaboration/training, the reciprocal U.S. Japan) entity the project should clearly delineated Description the qualifications the Japanese host the research facilities resources the host institution Submitted applications collaboration/training must include letter invitation biosketch the Japanese host(s). Workshop Fund Submitted applications joint workshops must include: Description the importance the proposed workshop investigators the field the larger neuroscience community Relevance the workshop the goals the BRCP the mission the participating NIH Institutes Centers Background anticipated outcomes Description the meeting content, including topics, sessions, a tentative agenda Plans foster potential collaborations between U.S. Japanese participants Justification the proposed workshop location duration Composition role the organizing committee, the name credentials key participants i.e., presenters, moderators) Plans disseminate information generated the proposed workshop the larger scientific community. Plans the inclusion junior investigators, women, racial/ethnic minorities, persons disabilities. Review Process: Administrative supplement requests undergo administrative evaluation NIH Program staff the participating Institutes Centers. Reporting: Reporting requirements be specified the terms conditions award applicable the supplemental activities. most non-competing continuation applications, progress report budget the supplement must included with, clearly delineated from, progress report budget the parent award. progress report must include information the activities supported the supplement even support future years not requested. Final Report Within month the completion all collaborative research/training efforts workshops, U.S. BRCP supported investigators required submit final report the NIH, detailing following information: Project objectives Significance Results/findings including list publications, presentations, dissemination material research grant applications resulting the collaboration/training workshop Outcome collaboration/training workshop how benefits NIH supported research plans continued collaboration the Japanese investigator(s) Inquiries Please direct inquiries to: Scientific/Research Contact(s) Stacey D. ChambersNational Institute Neurological Disorders Stroke NINDS)Telephone: 301-496-0690 Email: chambers@ninds.nih.go Coryse St. Hillaire-Clarke, Ph.D.National Institute Aging NIA)Telephone: 301-827-6944Email: sthillaireclacn@mail.nih.gov Shumin Wang, Ph.D.National Institute Biomedical Imaging Bioengineering NIBIB)Telephone: 301-594-9001Email: shumin.wang@nih.gov Da-Yu Wu, Ph.D. National Institute Drug Abuse NIDA) Telephone: 301-443-1887 Email: wudy@nida.nih.gov Susan L. Sullivan, Ph.D.National Institute Deafness amp; Communication Disorders NIDCD)Telephone: 301-451-3841Email: sullivaS@nidcd.nih.gov Yolanda F. Vallejo, Ph.D.National Institute Dental Craniofacial Research NIDCR)Telephone: 301-827-4655Email: Yolanda.Vallejo@nih.gov Jonathan A. Hollander, Ph.D. National Institute Environmental Health Sciences NIEHS) Telephone: 919-541-9467 Email: jonathan.hollander@nih.gov Miri Gitik, Ph.D. National Institute Mental Health NIMH) Telephone: 301-827-3523 Email: miri.gitik@nih.gov Inna Belfer, M.D., Ph.D. National Center Complementary Integrative Health NCCIH) Telephone: 301-435-1573 Email: inna.belfer@nih.gov Danilo A. Tagle, Ph.D., M.S. National Center Advancing Translational Sciences NCATS) Telephone: 301-594-8064 Email: danilo.tagle@nih.gov Financial/Grants Management Contact(s) Chief Grants Management Officer National Institute Neurological Disorders Stroke NINDS) Email: ChiefGrantsManagementOfficer@ninds.nih.gov Jennifer Edwards National Institute Aging NIA) Telephone: 301-827-6689 Email: edwardsj@mail.nih.gov James Huff National Institute Biomedical Imaging Bioengineering NIBIB) Telephone: 301-451-4786 Email: huffj@mail.nih.gov Cheryl Nathaniel National Institute Drug Abuse NIDA) Telephone: 202-526-0108 Email: nathanic@nida.nih.gov Christopher MyersNational Institute Deafness Other Communication Disorders NIDCD) Telephone: 301-402-0909 Email: myersc@mail.nih.gov Dede Rutberg National Institute Dental Craniofacial Research NIDCR) Telephone: 301-594-4798 Email: rutbergd@mail.nih.gov James R. Williams National Institute Environmental Health Sciences NIEHS) Telephone: 919-541-1403 Email: james.williams3@nih.gov Tamara KeesNational Institute Mental Health NIMH)Telephone: 301-443-8811Email: tkees@mail.nih.gov Shelley M. CarowNational Center Complementary Integrative Health NCCIH)Telephone: 301-594-3788Email: carows@mail.nih.gov Karen BrummettNational Center Advancing Translational Sciences NCATS)Telephone: 301-594-6268Email: Karen.Brummett@nih.gov

NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed)

PA
Tuesday, May 5, 2020
Monday, May 8, 2023
K99/R00
PA-20-188

Funding Opportunity Purpose

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Required)

PA
Tuesday, May 5, 2020
Monday, May 8, 2023
K99/R00
PA-20-187

Funding Opportunity Purpose

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

NIH Pathway to Independence Award (Parent K99/R00 Independent Basic Experimental Studies with Humans Required)

PA
Tuesday, May 5, 2020
Monday, May 8, 2023
K99/R00
PA-20-189

Funding Opportunity Purpose

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)

PA
Tuesday, May 5, 2020
Monday, May 8, 2023
R01
PA-20-184

Funding Opportunity Purpose

The NIH Research Project Grant supports a discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s). This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate Clinical Trials Required or Clinical Trial Optional FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System

Notice of Special Interest
Thursday, April 30, 2020
Thursday, April 15, 2021
333
NOT-NS-20-051

Funding Opportunity Purpose

Notice Special Interest NOSI): Availability Urgent Competitive Revisions Administrative Supplements Research Biological Effects the 2019 Novel Coronavirus the Nervous System Notice Number: NOT-NS-20-051 Key Dates Release Date: April 30, 2020 First Available Due Date: 01, 2020 Expiration Date: April 15, 2021 Related Announcements NOT-NS-20-074 Notice Change Eligible Activity Codes NOT-NS-20-051 PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) NOT-OD-20-026 New NIH FORMS-F" Grant Application Forms Instructions Coming Due Dates or after 25, 2020 Issued National Institute Neurological Disorders Stroke NINDS) National Institute Alcohol Abuse Alcoholism NIAAA) - New participating organization of 05/08/2020 due dates on/after 05/08/2020 Purpose NINDS issuing Notice Special Interest NOSI) highlight urgent need research Coronavirus Disease 2019 COVID-19) on biological effects the nervous system its causative agent, severe acute respiratory syndrome coronavirus 2 SARS-CoV-2). Research interest must fall within NINDS’s scientific mission, is support basic, translational, clinical neuroscience research expand fundamental knowledge the brain nervous system to that knowledge reduce burden neurological disease. Research Objectives order rapidly improve our understanding the neurological consequences infection SARS-CoV-2 of COVID-19, NINDS encouraging submission applications supplements address biology, pathophysiology, prevention, diagnosis, sequelae, treatment the 2019 Novel Coronovirus are directly related the NINDS mission. National Institute Alcohol Abuse Alcoholism NIAAA) accept supplements NIAAA-supported projects fall within scope the NOT-NS-20-051 are relevant the mission the NIAAA. Specifically, NIAAA interested studies integrate alcohol exposure research topics outlined the announcement better understand, prevent, mitigate of neurobiological consequences SARS-CoV-2 infection COVID-19 individuals have Alcohol Disorders AUD). NIAAA encourages supplements be collaborative nature include appropriate neurological expertise the proposed projects. Application Submission Information Applications this initiative must submitted using of following opportunity announcements the subsequent reissued equivalent. PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) PA-18-935 - Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional) Applications research fall within scope an existing NINDS award should submitted through PA-18-591 (Parent Admin Supp Clinical Trial Optional). Eligible activity codes fare limited the mechanisms listed in PA-18-591. Applications research involve change the original scope an active award, still falls within mission the NINDS must apply through PA-18-935 Urgent Competitive Revision Existing NIH Grants Cooperative Agreements Urgent Supplement - Clinical Trial Optional). Eligible activity codes applications to PA-18-935 are limited the following mechanisms: P01, P50, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U19, U24, U44, U54, UG3, UH3). Scope defined the original specific aims, objectives, purposes a grant, methodology, approach, analyses other activities, the tools, technologies, timeframes needed meet grant's objectives. Changes include shifting research emphasis one disease area another, changing any aspects research involving vertebrate animals human subjects. you unsure whether application involve change scope, contact NINDS program director. instructions the SF424 R&R) Application Guide and PA-18-591 or PA-18-935 must followed, the following additions: funding consideration, applicants must include “NOT-NS-20-051"(without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. project period the supplement must exceed year. Application budgets not exceed 200,000 direct costs. Exceptions this budget limit be only NINDS pre-approval will only approved under very rare circumstances where work immediately impact public health. Research Strategy section the application limited 6 pages parent award must active the supplement application submitted e.g. within originally reviewed approved project period), regardless the time remaining the current project. Grants multi-year funding RF1) have additional constraints. Applicants these grants should contact program official determine eligibility. applications including those multi-project activity codes) must submitted electronically using single-project application form package Administrative supplement applications to PA-18-591 must the application form package the Competition ID contains FORMS-E-ADMINSUPP”. FOA be reissued application form packages containing FORMS-F-ADMINSUPP” May 25, 2020. Submissions to PA-18-591 must completed June 25, 2020 see NOT-OD-20-026 for details.) Submissions the reissued FOA be accepted or after 25, 2020 through expiration date this Notice. addition, process Streamlined Submissions using eRA Commons cannot used this initiative. Competitive revision applications to PA-18-935 must the application form package the Competition ID NOT-NS-20-051-FORMS-E." FOA be reissued a NOT-NS-20-051-FORMS-F” package May 25, 2020. Submissions to PA-18-935 must completed June 25, 2020. Submissions the reissued FOA be accepted or after 25, 2020 through expiration date this Notice. Applications be accepted a rolling basis from April 15, 2020 April 14, 2021 5:00 PM local time of applicant organization. NOSI expires on April 15, 2021. application submitted response this NOSI is received after expiration date be withdrawn Applications must specifically address issues potential biohazards, all research must conducted compliance the health safety requirements found the NIH Grants Policy Statement. Applications are responsive the terms this Notice not considered. Investigators planning apply response this NOSI strongly encouraged contact discuss proposed research/aims the Program Official the Parent Award advance better determine appropriateness interest the NINDS.   Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: Scientific/Research Contact(s) Please contact program officer your active award. NIAAA grantees, please direct inquiries Dr. Changhai Cui changhai.cui@nih.gov).

Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)

PA
Thursday, April 23, 2020
Monday, May 8, 2023
K02
PA-20-173

Funding Opportunity Purpose

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as prospective basic science studies involving human participants. These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R01 Clinical Trials Not Allowed)

PAR
Monday, April 13, 2020
Monday, March 6, 2023
R01
PAR-20-165

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. Applicants are encouraged to propose novel and innovative research that will break new ground or extend previous discoveries toward new directions.

Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R21 Clinical Trials Not Allowed)

PAR
Monday, April 13, 2020
Monday, May 8, 2023
R21
PAR-20-168

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. The R21 Grant mechanism is intended to support innovative, high impact research projects. Such projects would either 1) generate pilot data to assess the feasibility of a novel avenue of investigation; 2) involve high risk experiments that could lead to a breakthrough in ME/CFS; 3) demonstrate the feasibility of new technologies that could have a major impact on ME/CFS research. Proposals submitted under this mechanism should be limited to those with the potential for truly ground-breaking impact.

Pages